Quest Diagnostics Rallies Ahead of Earnings as Investors Weigh Growth Initiatives

Quest Diagnostics (DGX) is up 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to positioning ahead of Quest Diagnostics' second-quarter 2026 earnings release scheduled for July 23, 2026, with investors likely expecting another solid report after the company beat first-quarter expectations and raised full-year revenue and EPS guidance in April. Recent expansion of its oncology testing footprint and broader access for Haystack MRD could also be reinforcing confidence in growth beyond the core lab business.

Details:

Quest Diagnostics said it will report second-quarter 2026 financial results before the market opens on July 23, 2026, which can draw speculative buying ahead of the release.

In first-quarter 2026, the company posted revenue growth of 9.2% and raised its full-year 2026 revenue and adjusted EPS outlook, giving investors a stronger recent operating backdrop.

On July 8, Quest Diagnostics announced a pilot that extends oncology test access through OncoEMR MPI, expanding availability of Haystack MRD to community oncology providers.

In late June, Quest Diagnostics received New York State approval for Haystack MRD, broadening access to its ctDNA minimal residual disease test for patients with solid tumor cancers.

Sources:

Quest Diagnostics Investor Relations, Quest Diagnostics Newsroom, Kiplinger

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DGX Insider Trading Activity

$DGX insiders have traded $DGX stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:

CATHERINE T. DOHERTY (EVP, Regional Businesses) has made 0 purchases and 8 sales selling 33,788 shares for an estimated $6,964,736.
J. E. DAVIS (CEO and President) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $4,066,600.
KARTHIK KUPPUSAMY (SVP, Clinical Solutions) has made 0 purchases and 2 sales selling 10,775 shares for an estimated $2,167,772.
PATRICK PLEWMAN (SVP for Diagnostic Services) has made 0 purchases and 4 sales selling 9,885 shares for an estimated $2,025,173.
MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 5,515 shares for an estimated $1,136,514.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DGX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DGX Hedge Fund Activity

We have seen 429 institutional investors add shares of $DGX stock to their portfolio, and 423 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS GROUP AG removed 412,114 shares (-37.0%) from their portfolio in Q1 2026, for an estimated $80,766,101
GOLDMAN SACHS GROUP INC removed 359,969 shares (-21.1%) from their portfolio in Q1 2026, for an estimated $70,546,724
FIDUCIARY MANAGEMENT INC /WI/ removed 325,935 shares (-31.1%) from their portfolio in Q1 2026, for an estimated $63,876,741
FREESTONE GROVE PARTNERS LP removed 303,524 shares (-98.2%) from their portfolio in Q1 2026, for an estimated $59,484,633
M.D. SASS, LLC added 299,459 shares (+inf%) to their portfolio in Q1 2026, for an estimated $58,687,974
BLACKROCK, INC. removed 286,926 shares (-3.0%) from their portfolio in Q1 2026, for an estimated $56,231,757
JANE STREET GROUP, LLC removed 286,305 shares (-97.8%) from their portfolio in Q1 2026, for an estimated $56,110,053

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DGX Government Contracts

We have seen $135,625,604 of award payments to $DGX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

VISN 7 REFERENCE LAB SERVICES: $8,250,000
PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMY: $7,899,999
REFERENCE LAB TESTING - ADD AND EXERCISE OPTION: $3,025,981
REFERENCE LAB TESTS: $2,748,684

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DGX Congressional Stock Trading

Members of Congress have traded $DGX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $DGX stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/30, 03/27 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DGX Analyst Ratings

Wall Street analysts have issued reports on $DGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 02/11/2026

To track analyst ratings and price targets for $DGX, check out Quiver Quantitative's $DGX forecast page.

$DGX Price Targets

Multiple analysts have issued price targets for $DGX recently. We have seen 9 analysts offer price targets for $DGX in the last 6 months, with a median target of $225.0.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $229.0 on 04/22/2026
Luke Sergott from Barclays set a target price of $230.0 on 04/22/2026
David Macdonald from Truist Securities set a target price of $225.0 on 04/22/2026
Kevin Caliendo from UBS set a target price of $220.0 on 04/22/2026
Elizabeth Anderson from Evercore ISI Group set a target price of $210.0 on 04/08/2026
Ann Hynes from Mizuho set a target price of $235.0 on 02/12/2026
Tycho Peterson from Jefferies set a target price of $220.0 on 02/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.